Asia On The Move: Alliance Boots Partner Nanjing Pharma President Quits, BIO’s EVP Leaves For Celgene
This article was originally published in PharmAsia News
Nanjing Pharma has seen three top executive departures in recent months, which could impact its collaboration with U.K. pharmacy giant Alliance Boots. Meanwhile, personnel changes also took place at BIO, Mundipharma, Beigene, Catalent Pharma Solutions and Zhejiang FDA.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.